1346575-64-1

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Pyridinone, 3-(aMinoMethyl)-6-Methyl-4-propylis used as a potential pharmaceutical compound for its structural features that may contribute to the development of new drugs. Its aminomethyl, methyl, and propyl groups could be utilized in the synthesis of various drug molecules, targeting specific therapeutic areas.
Used in Agrochemical Industry:
2(1H)-Pyridinone, 3-(aMinoMethyl)-6-Methyl-4-propylis used as a potential agrochemical compound for its structural features that may be applicable in the development of new pesticides or herbicides. 2(1H)-Pyridinone, 3-(aMinoMethyl)-6-Methyl-4-propyl-'s unique functional groups could be employed to create novel agrochemicals with improved efficacy and selectivity.

InChI:InChI=1S/C10H16N2O.C2H4O2/c1-3-4-8-5-7(2)12-10(13)9(8)6-11;1-2(3)4/h5H,3-4,6,11H2,1-2H3,(H,12,13);1H3,(H,3,4)

Upstream product

• 5609-09-6 3-hepten-2-one 
• 5609-09-6 trans 3-hepten-2-one 

Downstream Products

• 1347232-05-6 6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide 
• 1346702-88-2 6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide hydrochloride 
• 1427853-73-3 1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1346704-33-3 GSK343 

Relevant academic research and scientific papers

EZH2 inhibitor as well as preparation of EZH2 inhibitor and application of EZH2 inhibitor in anti-tumor treatment

The invention discloses an EZH2 inhibitor as well as preparation of the EZH2 inhibitor and application of the EZH2 inhibitor in anti-tumor treatment. The EZH2 inhibitor has a structure represented bya general formula I shown in the description, wherein de

SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF

The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

EZH2 INHIBITORS AND USES THEREOF

The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.

METHOD OF TREATMENT

The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Identification of potent, selective, cell-Active inhibitors of the histone lysine methyltransferase EZH2

The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-Active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These compounds are small molecule chemical tools that would be useful to further explore the biology of EZH2.